VALEO PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.66 CAD | -.--% |
|
+1.54% | -10.81% |
| Apr. 25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
Valuation
| Fiscal Period: Oktober | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15.01 | 49.28 | 64.62 | 53.42 | 14.3 | 11.35 | - |
| Enterprise Value (EV) 1 | 15.01 | 49.28 | 64.62 | 53.42 | 14.3 | 63.88 | 11.35 |
| P/E ratio | -3.79 x | - | - | -2.03 x | -0.45 x | -0.58 x | -0.88 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.28 x | 6.6 x | 4.77 x | 1.93 x | 0.27 x | 0.19 x | 0.15 x |
| EV / Revenue | 2.28 x | 6.6 x | 4.77 x | 1.93 x | 0.27 x | 1.05 x | 0.15 x |
| EV / EBITDA | - | -19 x | -5.31 x | -3.68 x | -1.31 x | -31.9 x | 4.46 x |
| EV / FCF | - | -9,194,584 x | -4,888,866 x | -1,851,134 x | - | - | - |
| FCF Yield | - | -0% | -0% | -0% | - | - | - |
| Price to Book | - | - | - | -2.95 x | -0.31 x | - | - |
| Nbr of stocks (in thousands) | 56,659 | 64,004 | 78,800 | 82,190 | 98,634 | 98,675 | - |
| Reference price 2 | 0.2650 | 0.7700 | 0.8200 | 0.6500 | 0.1450 | 0.1150 | 0.1150 |
| Announcement Date | 2/27/20 | 2/24/21 | 2/28/22 | 1/30/23 | 1/29/24 | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Oktober | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.577 | 7.47 | 13.56 | 27.7 | 53.91 | 61 | 75.83 |
| EBITDA 1 | - | -2.6 | -12.18 | -14.5 | -10.9 | -2 | 2.543 |
| EBIT 1 | - | -4.343 | -12.94 | -19.6 | -17.23 | -6.434 | -0.655 |
| Operating Margin | - | -58.14% | -95.45% | -70.77% | -31.96% | -10.55% | -0.86% |
| Earnings before Tax (EBT) 1 | - | - | - | -26.92 | -27.81 | -18.01 | -12.41 |
| Net income 1 | - | - | - | -25.7 | -27.81 | -18.01 | -12.41 |
| Net margin | - | - | - | -92.78% | -51.58% | -29.53% | -16.37% |
| EPS 2 | -0.0700 | - | - | -0.3200 | -0.3200 | -0.2000 | -0.1300 |
| Free Cash Flow | - | -5.36 | -13.22 | -28.86 | - | - | - |
| FCF margin | - | -71.75% | -97.49% | -104.19% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/24/21 | 2/28/22 | 1/30/23 | 1/29/24 | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: October | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 4.241 | 4.768 | 6.073 | 12.7 | 13.16 | 13.56 | 14.1 | 13.11 | 13.54 | 15.5 | 16 | 16 |
| EBITDA 1 | -6.738 | -4.4 | -3.775 | -2.903 | -2.9 | -2.213 | -1.694 | -2.5 | -4.5 | -2.081 | -2.2 | -0.5 | 0.4 |
| EBIT | - | -4.895 | -3.943 | -3.526 | -7.24 | -3.862 | -2.802 | -3.43 | -7.134 | -4.863 | - | - | - |
| Operating Margin | - | -115.42% | -82.7% | -58.06% | -57.01% | -29.34% | -20.67% | -24.33% | -54.42% | -35.92% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -5.863 | -5.098 | -4.735 | -11.22 | -6.248 | -6.477 | -5.838 | -5.455 | -6.872 | -5.048 | -3.919 | -2.922 |
| Net income | - | -5.863 | -5.098 | -4.735 | -9.3 | -6.248 | -6.477 | -5.8 | -5.455 | -6.872 | - | - | - |
| Net margin | - | -138.25% | -106.92% | -77.97% | -73.23% | -47.47% | -47.77% | -41.13% | -41.62% | -50.76% | - | - | - |
| EPS 2 | - | -0.0700 | -0.0600 | -0.0600 | -0.1300 | -0.0800 | -0.0800 | -0.0700 | -0.1000 | -0.0800 | -0.0500 | -0.0400 | -0.0250 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 3/24/22 | 6/14/22 | 9/13/22 | 1/30/23 | 3/15/23 | 6/13/23 | 9/13/23 | 1/29/24 | 3/14/24 | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: October | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 52.5 | - |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -26.26 x | - |
| Free Cash Flow | - | -5.36 | -13.2 | -28.9 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | -0.2200 | -0.4700 | - | - |
| Cash Flow per Share | - | - | - | -0.4400 | -0.1800 | - | - |
| Capex | - | 0.06 | 0.9 | 0.36 | - | - | - |
| Capex / Sales | - | 0.83% | 6.65% | 1.3% | - | - | - |
| Announcement Date | 2/27/20 | 2/24/21 | 2/28/22 | 1/30/23 | 1/29/24 | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.115
CAD
Average target price
0.5
CAD
Spread / Average Target
+334.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- VPH Stock
- VPH Stock
- Financials Valeo Pharma Inc.
